Mifepristone and misoprostol in California pharmacies after modifications to the Risk Evaluation and Mitigation Strategy Program.

Autor: Beshar I; Department of Obstetrics & Gynecology, Stanford University, Palo Alto, CA, USA. Electronic address: isabel.beshar@gmail.com., Miller HE; Division of Maternal Fetal Medicine, Stanford University, CA, USA., Kruger S; Department of Obstetrics & Gynecology, Stanford University, Palo Alto, CA, USA., Henkel A; Division of Family Planning, Department of Obstetrics & Gynecology, Stanford University, Palo Alto, CA, USA.
Jazyk: angličtina
Zdroj: Contraception [Contraception] 2024 Sep; Vol. 137, pp. 110506. Date of Electronic Publication: 2024 May 26.
DOI: 10.1016/j.contraception.2024.110506
Abstrakt: In January 2023, the Food & Drug Administration modified the Risk Evaluation and Mitigation Strategy program regulating mifepristone to allow direct dispensation from retail pharmacies. In June 2023, we conducted a random, distributive survey of pharmacies in California using secret shopper methodology to investigate the feasibility of accessing mifepristone. One pharmacy had mifepristone immediately available (<24 hours), and misoprostol availability was limited. Accessibility to misoprostol varied by type of pharmacy (p < 0.01), but not by region. Even in a reproductive freedom state, access to mifepristone and misoprostol from outpatient retail pharmacies remains limited.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: